Transaction DateRecipientSharesTypePriceValue
1st December 2020Huw M. Nash2,719Open or private sale$49.19$133,743.53
1st December 2020Huw M. Nash100Open or private sale$51.45$5,145.00
1st December 2020Huw M. Nash2,481Open or private sale$50.02$124,103.09
1st December 2020Huw M. Nash5,700Exercise of derivative$2.19$12,483.00
1st December 2020Huw M. Nash400Open or private sale$52.72$21,088.00
27th November 2020Edward M. Md Kaye12,152Open or private sale$50.00$607,600.00
25th November 2020Edward M. Md Kaye12,848Open or private sale$50.00$642,400.00
24th November 2020Tree Partners Iv, L.P. Apple375,000Open or private purchase$39.00$14,625,000.00
24th November 2020Seth Loring Harrison375,000Open or private purchase$39.00$14,625,000.00
10th November 2020Huw M. Nash13,414Exercise of derivative$2.19$29,376.66
Stoke Therapeutics
Stoke Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.


Ticker: STOK
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1623526
Employees:
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals